Apolipoprotein E ε4 Prevalence in Alzheimer's Disease Patients Varies across Global Populations: A Systematic Literature Review and Meta-Analysis

被引：120

作者：

Crean, Sheila ^{[1
]}

Ward, Alex ^{[1
]}

Mercaldi, Catherine J. ^{[1
]}

Collins, Jenna M. ^{[1
]}

Cook, Michael N. ^{[2
]}

Baker, Nicole L. ^{[2
]}

Arrighi, H. Michael ^{[3
]}

机构：

[1] United BioSource Corp, Lexington, MA 02420 USA

[2] Pfizer Inc, Collegeville, PA USA

[3] Janssen Alzheimer Immunotherapy Res & Dev LLC, San Francisco, CA USA

来源：

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS | 2011年 / 31卷 / 01期

关键词：

Alzheimer's disease; Apolipoprotein E; Apolipoprotein E epsilon 4; prevalence in Alzheimer's disease; E GENOTYPE; APOE-EPSILON-4; ALLELE; AFRICAN-AMERICANS; ASSOCIATION; ONSET; RISK; FREQUENCY; DEMENTIA; AGE; MODEL;

D O I：

10.1159/000321984

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Background: The epsilon 4 allele of apolipoprotein E (APOE) is associated with Alzheimer's disease (AD). However, attributable risk due to APOE4 varies by region and by race/ethnicity. Methods: A literature review and meta-analysis were conducted to estimate the prevalence of APOE4 by geographic area among AD patients. Results: Although estimates varied significantly by study design and case definition, AD patients recruited in Asian and southern European/Mediterranean communities seemed to have significantly lower E4 carrier status estimates (37 and 43%) than those recruited in North America (58%) or northern Europe (64%; all: p < 0.05). Conclusions: APOE4 genotype frequency varies among AD patients in regional patterns similar to that of the general population. Study level differences may also contribute to the heterogeneity of published estimates of APOE4 in AD cases. Copyright (C) 2010 S. Karger AG, Basel

引用

页码：20 / 30

页数：11

共 25 条

[1] ALDERSON P, 2004, COCHRANE COLLABORATI
[2] [Anonymous], STAT METHODS METAANA
[3] [Anonymous], 2005, CHIN J CLIN REHAB
[4] A RANDOM-EFFECTS REGRESSION-MODEL FOR METAANALYSIS
BERKEY, CS
HOAGLIN, DC
MOSTELLER, F
COLDITZ, GA
[J]. STATISTICS IN MEDICINE, 1995, 14 (04) : 395 - 411
[5] Systematic reviews: Synthesis of best evidence for clinical decisions
Cook, DJ
Mulrow, CD
Haynes, RB
[J]. ANNALS OF INTERNAL MEDICINE, 1997, 126 (05) : 376 - 380
[6] Apolipoprotein E (APOE) allele distribution in the world.: Is APOE*4 a 'thrifty' allele?
Corbo, RM
Scacchi, R
[J]. ANNALS OF HUMAN GENETICS, 1999, 63 : 301 - 310
[7] Apolipoprotein E ε4 allele frequency and age at onset of Alzheimer's disease
Davidson, Yvonne
Gibbons, Linda
Pritchard, Antonia
Hardicre, Jayne
Wren, Joanne
Stopford, Cheryl
Julien, Camille
Thompson, Jennifer
Payton, Antony
Pickering-Brown, Stuart M.
Pendleton, Neil
Horan, Michael A.
Burns, Alistair
Purandare, Nitin
Lendon, Corinne L.
Neary, David
Snowden, Julie S.
Mann, David M. A.
[J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2007, 23 (01) : 60 - 66
[8] METAANALYSIS IN CLINICAL-TRIALS
DERSIMONIAN, R
LAIRD, N
[J]. CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 177 - 188
[9] Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041
[10] Association between apolipoprotein E genotype and Alzheimer disease in African American subjects
Graff-Radford, NR
Green, RC
Go, RCP
Hutton, ML
Edeki, T
Bachman, D
Adamson, JL
Griffith, P
Willis, FB
Williams, M
Hipps, Y
Haines, JL
Cupples, LA
Farrer, LA
[J]. ARCHIVES OF NEUROLOGY, 2002, 59 (04) : 594 - 600

← 1 2 3 →